Document is current
Any future updates will be listed below
-
Authors
Berko, Esther R.
Witek, Gabriela M. http://orcid.org/0000-0003-2635-773X
Matkar, Smita
Petrova, Zaritza O.
Wu, Megan A.
Smith, Courtney M.
Daniels, Alex
Kalna, Joshua
Kennedy, Annie
Gostuski, Ivan
Casey, Colleen http://orcid.org/0009-0004-9259-1035
Krytska, Kateryna
Gerelus, Mark http://orcid.org/0000-0001-8986-4523
Pavlick, Dean
Ghazarian, Susan
Park, Julie R.
Marachelian, Araz
Maris, John M. http://orcid.org/0000-0002-8088-7929
Goldsmith, Kelly C.
Radhakrishnan, Ravi http://orcid.org/0000-0003-0686-2851
Lemmon, Mark A. http://orcid.org/0000-0002-3379-5319
Mossé, Yaël P. http://orcid.org/0000-0002-3463-0399
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (CA217959, CA140198)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Solving Kids' Cancer
Cookies for Kids Cancer The EVAN Foundation
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (GM122485)
- License Information
-
More Information
Article History
Received: 8 January 2023
Accepted: 20 April 2023
First Online: 5 May 2023
Competing interests
: Y.P.M. is the Principal Investigator of the NANT Phase 1 trial of lorlatinib and is a consultant for Pfizer. No research funding from Pfizer was received for this study. Y.P.M. has previously received research funding from Pfizer and Novartis. Y.P.M. has also served as a consultant for Lilly, Auron Therapeutics, and Jumo Health. Y.P.M. serves as a member of the Data and Safety Monitoring Committee for the ASCO TAPUR study and receives honoraria for this role. D.P. is an employee of Foundation Medicine. The remaining authors declare no competing interests.
